⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
HOTH News
Hoth Therapeutics, Inc. Common Stock
Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients
prnewswire.com
HOTH
Form 8-K
sec.gov
HOTH
Form 8-K
sec.gov
HOTH
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
prnewswire.com
HOTH
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide
prnewswire.com
HOTH
Form 8-K
sec.gov
HOTH
Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
prnewswire.com
HOTH
Hoth Therapeutics Announces $2.0 Million Registered Direct Offering
prnewswire.com
HOTH
Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six
prnewswire.com
HOTH
Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology
prnewswire.com
HOTH